New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For LH;FLIR;SNTA;PCL;ESI;DNB From The Last 14 Days
Check below for free stories on LH;FLIR;SNTA;PCL;ESI;DNB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
July 31, 2014
14:41 EDTLHFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
Subscribe for More Information
11:29 EDTLHFDA announces steps to ensure reliable diagnostic test results
Subscribe for More Information
July 29, 2014
10:00 EDTPCLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:07 EDTPCLPlum Creek Timber downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Plum Creek Timber to Market Perform following the Q2 report citing weaker than expected guidance.
July 28, 2014
18:31 EDTPCLOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cognex (CGNX), up 16.4% after reporting second quarter results and third quarter revenue guidance above analyst expectations... HealthSouth (HLS), up 7.4% after reporting second quarter results and increasing fiscal 2014 EPS and Adjusted EBITDA guidance... Amkor Technology (AMKR), up 6.4%... Integrated Device (IDTI), up 7.6% after reporting first quarter results... Masco (MAS), up 4.8%. ALSO HIGHER: Darden Restaurants (DRI), up 4.6% following the company's announcement that chairman and CEO Clarence Otis will step down and the board will separate the chairman and CEO roles, appointing lead independent director Charles Ledsinger, Jr., as independent non-executive chairman... Arrowhead Research (ARWR), up 16.5% following positive comments made by CEO Christopher Anzalone, Ph.D. in an interview on CNBC. DOWN AFTER EARNINGS: Herbalife (HLF), down 11.5% after reporting disappointing second quarter results and giving guidance for the third quarter and fiscal 2014... Alliance Fiber Optic (AFOP), down 9.7%... Plum Creek Timber (PCL), down 2.8%... Eastman Chemical (EMN), down fractionally after reporting quarterly results. ALSO LOWER: TCP Capital (TCPC), down 3.1% after filing to sell $5.4M shares of common stock.
16:23 EDTPCLPlum Creek Timber slips after results, first look
Subscribe for More Information
16:14 EDTPCLPlum Creek Timber sees FY14 timber harvest at low end of 20M-21M ton range
The company has adjusted its harvest plans in certain local markets and now expects its 2014 timber harvest to come in at the low end of the 20M-21M ton range. The harvest deferral shifts approximately $15M of cash flow to the future, and reduces the earnings outlook by $13M, or 7c per share. During the third quarter, harvest levels in the Northern Resources segment are expected to seasonally rebound from second quarter lows when spring weather conditions limit timberland access. Southern Resources harvest volumes should increase from second quarter levels as Southern lumber production grows.
16:11 EDTPCLPlum Creek Timber CEO says expects meaningful growth in 2H14
Subscribe for More Information
16:09 EDTPCLPlum Creek Timber sees Q3 EPS 27c-32c, consensus 46c
16:09 EDTPCLPlum Creek Timber lowers FY14 EPS view to $1.05-$1.25 from $1.30-$1.50
FY14 consensus $1.39. The company has revised its earnings outlook for 2014 to reflect lower harvest volumes, expectations for slower log price growth, and the anticipated composition of real estate transactions in the second half of the year.
16:08 EDTPCLPlum Creek Timber reports Q2 EPS 31c, consensus 30c
Subscribe for More Information
16:07 EDTPCLPlum Creek Timber lowers FY14 outlook
15:47 EDTPCLNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include General Growth Properties (GGP), consensus 30c; Eastman Chemical (EMN), consensus $1.84; Range Resources (RRC), consensus 40c; XL Group (XL), consensus 83c; Plum Creek Timber (PCL), consensus 30c; Masco (MAS), consensus 28c; Jacobs Engineering (JEC), consensus 80c; Herbalife (HLF), consensus $1.57; W.R. Berkley (WRB), consensus 77c; HEALTHSOUTH (HLS), consensus 47c; Denny's (DENN), consensus 8c; Integrated Device Technology (IDTI), consensus 16c; Advent Software (ADVS), consensus 34c; Tile Shop Holdings (TTS), consensus 11c; Meru Networks (MERU), consensus (11c); Crane Co. (CR), consensus $1.16.
July 24, 2014
07:39 EDTFLIRFLIR Systems sees FY14 EPS $1.40-$1.50, consensus $1.41
Subscribe for More Information
07:38 EDTFLIRFLIR Systems reports Q2 EPS 31c, consensus 33c
Subscribe for More Information
July 22, 2014
10:01 EDTSNTASynta Pharmaceuticals strength a selling opportunity, says Stifel
Subscribe for More Information
09:07 EDTSNTASynta Pharmaceuticals data positive, says JMP Securities
JMP Securities believes that early top-line data indicates Synta's ganetespib plus current standard of care, low-dose Ara-C provide clinical benefit in high-risk elderly patients with newly diagnosed AML and MDS. The firm says the results increase its confidence in a positive GALAXY-2 outcome in NSCLC and broad applicability of ganetespib across a variety of tumor types. It keeps an Outperform rating on the stock.
July 21, 2014
16:32 EDTSNTASynta Pharmaceuticals advances ganetespib into Phase 3 extension of AML LI-1
Synta Pharmaceuticals announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial. AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who are not eligible for intensive chemotherapy. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date. Advancement into the Phase 3 extension follows an interim analysis of results from 50 patients who received the ganetespib-cytarabine combination in the Phase 2 portion of the trial. The primary efficacy outcome in Phase 2 was rate of complete response. Per protocol, the Phase 3 extension will include an interim futility analysis and enroll approximately 200 patients in the ganetespib-cytarabine and the cytarabine alone arms, for a total of approximately 400 patients. The primary efficacy endpoint for the Phase 3 extension will include overall survival. The Company is currently in discussion with study investigators, and anticipates providing additional details, including the timing of study milestones, as they become formalized. The AML LI-1 trial is the first of three multicenter, randomized studies supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to include a ganetespib treatment arm. AML LI-1 is being conducted under the auspices of the UKs National Cancer Research Institute Haematological Oncology Study Group, with investigators in Denmark, France, New Zealand, and the UK, and under the sponsorship of Cardiff University, UK. The other two studies, to be initiated later this year, are the AML-18 trial, evaluating ganetespib with standard DA in patients over 60 years old who can tolerate intensive chemotherapy, and the AML-19 trial, evaluating ganetespib in combination with conventional chemotherapy in younger patients with AML.
08:09 EDTLHLabCorp price target raised to $130 from $120 at Maxim
Subscribe for More Information
July 18, 2014
12:04 EDTLHLabCorp pullback a buying opportunity, says Maxim
Subscribe for More Information
11:25 EDTLHPiper awaits notable volume recovery to get more positive on LabCorp
Piper Jaffray views LabCorp's in-line quarter as positive and said restored TRICARE coverage may provide added upside, but the firm would like to see notable lab volume recovery and a pullback in the shares before becoming more positive on the stock. Piper raised its price target on the stock to $99 from $98 and maintains its Neutral rating on LabCorp.
10:03 EDTFLIROn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTLHLabCorp raises FY14 adjusted EPS to $6.50-$6.75 from $6.40-$6.70
Subscribe for More Information
06:43 EDTLHLabCorp: Q2 sales increase due to test volume
Total test volume increased 5.3%, while revenue per requisition decreased 2.0% due to test and payer mix. Reports Q2 operating income $246.7M, operating cash flow $207.4M, free cash flow $159M
06:41 EDTLHLabCorp reports Q2 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use